Abstract
Introduction
In Japan, approximately 90%of hepatocellular carcinoma (HCC) develops from chronic liver disease caused by chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) (1) . There is a group of HCCcases, however, having neither a serummarker of hepatitis B surface antigen (HBsAg) nor that of anti-HCV antibody (HCV-Ab), and this group of patients has been referred to as non-B, non-C (NBNC) HCC. Recently, the association of HBVinfection in NBNCHCCcases (2-4) as well as chronic hepatitis and cirrhosis without a known etiology has been reported (5, 6) .
Moreover, the frequent detection of HBVDNAin the serum and liver tissue of HBsAgnegative but HCV-Abpositive HCCpatients has been also demonstrated (7) . Very low levels of circulating HBVand/or a genomic variety of HBV have been suggested to be the reason why HBVDNAis detected by polymerase chain reaction (PCR) in these cases Circulating HBVFound in NBNCHCĈ^-^^^A merits such as core promoter and enhancer (17) (18) (19) . The ORFP encodes the viral polymerase, and it overlaps with the S region. The "a" determinant of the surface antigen spans the amino acid (aa) 124-147, overlapping the viral polymerase protein from aa 454 to 524. Thus mutations in the P gene might affect the antigenicity of the surface antigen. The ORFC encodes the nucleocapsid protein (hepatitis B core antigen, HBcAg) and hepatitis B e antigen (HBeAg). It has been considered that mutations in precore/core promoter might cause active hepatitis or fulminant hepatitis (20) ; however, asymptomaticcarriers with these mutations have now been detected in most countries. The PCR procedure enables detection of the HBVDNA in the serum, liver tissues, and peripheral blood mononuclear cells in HCCpatients who are HBsAgnegative but anti-HBs or anti-HBc positive, and the HBVDNAhas also been detected in rare cases without any serological markers (seronegative) (2, 3, 8 proteinase K and then DNAwas extracted by phenol/chloroform extraction followed by ethanol precipitation. The extracted DNAwas dissolved in 50 jlxI of distilled water.
Polymerase chain reaction coupled with Southern blo tting Prepared DNAwas subjected to PCRamplification and the PCR products were subsequently hybridized with whole HBVDNAby southern blotting, using two pairs of primers specific for the core and X region of the HBV genome ( Table 2 ). The first PCR was carried out to a final volume of 50 jlxI containing 5 |il of DNAsolution, 50 jjM each of dNTPs, 1.0 pi of each primer, lxPCR buffer (10 jiM Tris-HC1, 50 \M KC1, 1.5 \M MgCl2, and 0.001% gelatin), and 2.5 units of Ampli-Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT). Each amplification was done as follows; 40 cycles consisting of 94°C for 1 minute, 56°C for 1 minute, and 72°C for 1 minute. The second PCRfor the core region was performed in the same way as the first using 5 jlxI of the first PCR products. The amplified PCR products were investigated by staining with ethidium bromide on ultraviolet transilluminator after electrophoresis in 1.5% agarose gels. To confirm the results, Southern blotting using full-length HBVDNA(VG023, pBRHBadr72, developed by T Yoneyama, which was provided from Health Science Research Resources Bank) was performed. The PCR products were fractionated on 1% agarose gel and then transferred to a positive-charged nylon membraneaccording to the standard method of southern blotting. Then, the hybridization was performed with full-length HBVDNAusing a random primers labeling and detection kit (Amersham Pharmacia Biotech, Buckinghamshire, UK). Results were considered valid only if the same results were obtained in at least two separate experiments.
Sequence analysis
Direct sequence was performed for five NBNC HCC cases whose sera showed both HBsAg and anti-HCVnegative with no serology markers of HBVinfection at all. 
Statistical analysis
All data are expressed as mean ± S.D. The differences between the mean of two groups were analyzed by the KruskalWallis test. P values less than 0.05 were considered significant.
Results
Detection Figure 3 . Detection of HBVDNAby nested PCR(core region) and one step PCR(X region). Amplification was performed using 10 \ 1, 10, 102, 104, and 106copies of HBV DNA.
evaluate the sensitivity of this assay, various copies of HBV DNA (from 10 1 to 106 copies/reaction) were amplified by nested PCR (core region) and one-step PCR (X region). In the core region, HBVDNAwas successfully detected using 1 copy/reaction. On the other hand, 10 copies of HBVDNA were detectable in the X region (Fig. 3) . Table 3 alanine aminotransferase (ALT) and y-glutamyl transpeptidase (y-GTP), anti-HBs positivity, anti-HBc positivity, presence of liver cirrhosis, and excessive alcohol intake were not significantly different in the two groups, HBcAb positivity tended to be higher in the HBVDNA-positive group, though it was not statistically significant.
Sequence analysis
Wedetermined the nucleotide and amino acid sequences of the precore/core, polymerase, and preS/S regions of the five NBNCHCCpatients who had HBVDNAbut no other HBVserology markers (No. 1, 3, 6, 10, and ll in Table 3 ). Each nucleotide region was amplified by PCR, followed by direct sequence. Figure 5 shows the result of nucleotide sequence covering the precore/core and a part of the polymerase region. The PCRproducts of the five patients were found to be an expected size, indicating there were no major deletions in these regions. One point mutation at nt 1866 (A to C) was detected with the nucleotide sequence in the precore region in patient 1, which caused an amino acid substitution located at 18 from Gin to Pro. In the core region, a commonpoint mutation was detected at nt 2,288 (from C to A) in patient No. 3, 6, 10, and ll, causing an amino acid substitution located at 130 from Pro to Thr. With regards to the polymerase region, some nucleotide point mutations were discovered and subsequent amino acid substitutions were also detected at aa 168 (Phe to Leu), at 213 (Cys to Ser), and at 214 (Val to He). Figure 6 summarizes the amino acid substitution in each region.
Discussion
Occult HBVinfection has recently been identified by sensitive PCRassays in the serum of people whoare HBsAg negative. With a typical chronic HBVinfection, both HBV DNAand HBsAgshould be positive, and the absence of HBsAgindicates the absence of HBVand active viral replication. Occult HBV infection has been documented in a number of patient subgroups of HCCespecially those with HCVinfection (7). HBVDNAis present in the serum of up to 52% (21) of HCV-infected patients who are HBsAg negative and develop HCC. Many of these patients apparently cleared HBVand HBsAghad become negative but they still had demonstrable HBVDNAand proteins in the neoplastic and also in the non-neoplastic liver tissues. In such patients, chronic HCVinfection might be a predominant cause of HCCdevelopment. On the other hand, in this study, we detected HBVDNAin the sera of Japanese HCCpatients with the absence of both the HbsAgas well as the anti-HCV. The result of our study shows that occult HBVinfection existed in more than 60% of these NBNCHCCpatients by the sensitive PCR/Southern blotting method. The positive rate of serum HBVDNAdetected by nested PCRof core region and by one-step PCR of the X region was 65.4% (17/26) and 42.3% (ll/26), respectively. This suggests that the positive rates between core and X regions were different. However, Additional results showed that one-step PCRof the core region showed 38.5% (10/26) positivity, which is similar with that of Xregion in this study. These results indicate that the difference in the positivity rate might be due to the differences in sensitivity of PCRbetween the nested and one-step method. Although the investigated number was small, it is suggested that such an occult HBVinfection did not correlate with other HBVserology markers such as anti-HBs and anti-HBc in this study. with HCC and chronic hepatitis that are anti-HBc positive/anti-HBs negative, and the HBVDNAdetection rate is the lowest in seronegative subjects (8) . Thus, our data studying Japanese NBNCHCCpatients was quite different. The
HBVDNAdetection rate in seronegative patients was as high as that in seropositive cases. The same findings were also seen in another study from Japan (2), indicating that some regional difference maybe in effect. Recent studies have shownthat genotypes of HBVare correlated with the disease severity of chronic HBVinfection (22, 23 Japan, seems to be more damaging (24) . Thus, although we have not determined the HBV genotypes in our samples, genotypic differences might be one of the reasons for the difference between the results of studies from Japan and other countries. Among 16 cases with excessive alcohol intake, HBV DNAwas detected in ll cases (not significant vs. little drinkers). It should be questioned whether or not the alcohol intake is correlated with HCCdevelopment in the other 5 cases. Somereports have stated that there is no association between alcohol intake and the risk of liver cancer among the patients with chronic hepatitis (25, 26) . On the other hand, the opposite opinion has also been reported (27, 28) . Although it is controversial whether or not alcohol is an independent carcinogen of HCC, alcohol intake is causally involved in the development of liver cirrhosis.
Several possible mechanisms have been hypothesized to explain the lack of the HBsAgin these cases and the true reason is likely to be multifactorial. It has been said that the serum levels of HBVDNAaverage 102 copies/ml in individuals with occult HBVinfection (always less than 103 copies/ml), and in contrast, those in HBsAg-positive cases are 104 to 10s copies/ml (8 Brechot et al provide the evidence that occult HBVinfection exists and that most cases are related to very low levels of HBVrather than to HBVmutants that do not express or produce aberrant surface proteins and therefore are undetected by standard testing (8) . On the other hand, other data suggest viral factors can be responsible for occult HBVinfection. Numerous investigations have been reported interpreting the genetic variability of HBVin patients with occult HBVinfection. First, the mutations in the "a" determinant of S region have been described that could explain the lack of positive serologic assays for HBsAg (15, 16) . Moreover, because this epitope is the maintarget for neutralizing antibodies, mutations in this portion mayproduce "escape variants"
from the host immune system (33) (34) (35) . Mutations in the precore/core region have also been described in HBsAgnegative cases (12, 36) , and Uchida et al described some precore/core gene variants that may not induce serum HBsAgand anti-HBc in cases of acute or fulminant hepatitis (20) . Mutations in X region (8-nt deletion between nt 1,770 and 1,777) and several amino acid substitutions were reported, and Uchida et al postulated their substitutions lead to suppress the replication and expression of HBVDNAby changing HBx and core promotor function (19) . Mutations in the polymerase region have also been described to induce defects in the packaging of pregenomic RNA (36, 37) . Despite these investigations, the detailed mechanism for the lack of HBsAghas not been clarified. In the present study we detected HBVDNAin the NBNCHCCpatients without any serum HBVmarkers (seronegative), and succeeded in performing the sequence analysis of five patients in the precore/core region and a part of the polymerase region.
Several nucleotide point mutations were discovered in the polymerase region (nt 2,465, 2,810, 2,943, and 2,946) with amino acid substitutions in the 5' part (aa 168) and the spacer part (aa 213 and 214). As mentioned above, the 5' part of the polymerase gene encodes a terminal protein serving as a primer for reverse transcription of pregenomic RNA. In this sense, mutations in this position maydecrease the replication cycle of HBVDNA,and maycause the failure to detect any HBVmarkers. In the precore/core region sequence, two nucleotide mutations (nt 1,866 and 2,288) and subsequent amino acid substitutions (aa 18 and 160) were also detected in this study. The point mutation at nt 2,288 (from C to A) was commonin four of the five patients, and was not detected in the HBsAg-positive patients, therefore the ge- with HCC, and the prevalence of HBVDNAvaries from 5% to 80% (38) . Our data showed that it was present in 65% of the patients with NBNCHCC. This confusion may be due to the lack of well-designed prospective clinical assessment, HBVassociate with the development of HCC. In summary, HBVDNAwas detectable in the serum of patients with NBNCHCC. Although its clinical importance and the viral elimination have not been well documented, PCR-based screening is necessary to detect HBV DNAin patients with chronic liver disease especially when it is progressive and the etiology is unknown. A low level of HBV DNAand a variability of HBVgenome may explain the reason why serum detection of HBsAgcould fail. Wedetected several common nucleotide mutations and subsequent amino acid substitutions in the precore/core and the polymerase regions in patients without HBVserological markers, suggesting that these mutations might be involved in the lack of HBsAg.Finally, further studies are needed to clarify the relation between HBVDNAdetected in NBNCliver diseases and the development of HCC.
